A Dramatic Day for Dendreon

Shares surged Friday after an FDA panel voted in favor its Provenge treatment for prostate cancer

Dendreon's (DNDN) stock price surged nearly 150% on Mar. 30 after news that the U.S. Food and Drug Administration advisory committee vouched for the company's Provenge compound - even though the prostate cancer treatment may not kill tumors. Studies suggest, however, that the drug extends peoples' lives.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.